Retinal Vein Occlusion

Overview of branch retinal vein occlusion and central retinal vein occlusion.

What is a Retinal Vein Occlusion?

Arteries bring blood to the eye and veins bring blood back to the heart. While arteries have tough walls which usually become harder with age, veins have thin walls which remain pliant and soft throughout life. Because of the anatomy of the eye, the retinal veins are prone to occlusion. There are two main locations where retinal veins are occluded. One is at the crossing of a retinal arteriole and branch retinal vein. An occlusion at a crossing of a branch retinal arteriole and branch retinal vein causes a branch retinal vein occlusion. The second is at the main trunk of the retinal vein where it leaves the eye through the optic nerve. An occlusion at the main trunk of the retinal vein causes a central retinal vein occlusion. The picture shows a photo with dilated veins and retinal hemorrhages from a fresh central retinal vein occlusion.

What is a Branch Retinal Vein Occlusion?

A branch retinal vein occlusion occurs when, because of hardening of the arteries, a branch retinal artery compresses a branch retinal vein causing blockage of the vein and decreased circulation in the distribution of that branch retinal vein. (see image) [note: the branch arteries are really arteriols and the branch veins are really veinules] There are several possible treatments for branch retinal vein occlusion including intravitreal injections, laser, and even surgery. Patients with BRVO lose vision for several reasons: poor circulation, hemorrhage and macular edema (swelling). There is no treatment, at the moment, to increase circulation or to remove hemorrhage. The macular edema, however, does respond well to intravitreal injections with Lucentis, Avastin, or steroids.

Read more

What is a Central Retinal Vein Occlusion?

The inner layers of the retina receive their blood supply from the central retinal artery. The blood returns to the heart through the central retinal vein. Both vessels enter the eye through a small opening in the middle of the optic nerve. Either because this opening shrinks or because the artery hardens or because of circulations problems, the central retinal vein can become partially or completely occluded. When a patient develops a central retinal vein occlusion (CRVO), they lose some or most of their central vision. The retinal veins dilate and their are retinal hemorrhages. Patients often develop swelling of the central retina-cystoid macular edema--causing some of the vision loss. Without treatments, 25% of eyes improve, 50% stabilize, and 25% worsen. Monthly examinations of pateints with CRVO for less than six months are very important. Some patients with CRVO and very bad circulation, develop a severe type of glaucoma. In this situation, the eye becomes red and painful and without treatment, total visual loss can occur rapidly. If an examining doctor sees early signs that this complication may occur, then laser treatment can sometimes protect the eye. Once the pressure rise occurs, surgery can be helpful.

Read more

Retinal Vein Occlusion NEWS

Below are current articles from a Google News Feed on Retinal Vein Occlusion


Healio

Noninvasive, High-Resolution Functional Macular Imaging in Subjects With Retinal Vein Occlusion
Healio
Retinal vein occlusions (RVOs) are the second leading cause of blindness and common retinal morbidity occasioned by retinal vascular diseases worldwide, carrying a 15-year cumulative incidence of 1.8% and 0.5% for branch retinal vein occlusion (BRVO) ...


LANews By Abhishek Budholiya (press release) (blog)

Retinal Vein Occlusion Therapeutics Market to Incur Rapid Extension During 2015 – 2021
LANews By Abhishek Budholiya (press release) (blog)
Retinal vein occlusion (RVO) is one of the major cause of visual loss among the geriatric population. RVO is the second common cause of blindness after diabetic retinopathy. The RVO is mainly of two types based on the anatomy of the vein occlusion.


Retinal Vein Occlusion Pipeline Comparative Analysis 2017
E News Access (press release)
Retinal Vein Occlusion- Competitive Landscape, Pipeline and Market Analysis, 2017, report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding ...

and more »

Retinal Vein Occlusion Market Research Report 2017 to 2025
E News Access (press release)
Retinal Vein Occlusion- Competitive Landscape, Pipeline and Market Analysis, 2017, report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding ...


Keeping An Eye On Clearside Biomedical
Seeking Alpha
Uveitis Phase III top-line trial results in Q1 2018 will be the defining catalyst, given Clearside's limited cash runway. Successful trial results for the Uveitis Phase III could unlock larger markets such as macular edema associated with retinal vein ...
Clearside Biomedical, Inc. (NASDAQ:CLSD) Sees Significantly Lower Trading VolumeHugoPress

all 18 news articles »

How is the Age-Related Macular Degeneration Space Faring Now?
Nasdaq
The leading among them is Regeneron's Eylea. The drug is approved for the treatment of wet AMD, diabetic macular edema (DME), macular edema following retinal vein occlusion among others. Sales of the drug in the United States came in at $3.3 billion in ...

and more »

pharmaphorum

NICE recommends Bayer drug for severe short-sightedness
pharmaphorum
The drug is also licensed in several other ophthalmology indications – wet age-related macular degeneration, visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO), and visual impairment due to macular oedema ...

and more »

AOP

Eylea approval
AOP
Eylea is already licensed in the UK for treating age-related macular degeneration, visual impairment due to macular oedema secondary to central retinal vein occlusion and visual impairment due to macular oedema secondary to branch retinal vein occlusion.


PharmaTimes

NICE nod for new Eylea indication
PharmaTimes
... UK for the treatment of wet age-related macular degeneration, visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO) and visual impairment due to macular oedema secondary to branch retinal vein occlusion (BRVO).
NICE green light for Eylea in mCNVThe Pharma Letter

all 2 news articles »

Clearside Biomedical, Inc. (NASDAQ:CLSD) Experiences Lighter than Usual Trading Volume
Finance Daily
Its products include CLS-1001 for the treatment of macular edema associated with non-infectious uveitis; CLS-1003 for the treatment of macular edema associated with retinal vein occlusion; and CLS-1002 program for the treatment of wet age-related ...

and more »

Cardiovascular Business

Researchers confirm link between retinal vein occlusion, heart attack
Cardiovascular Business
In a large, retrospective study of the Taiwan population, researchers found individuals with retinal vein occlusion (RVO) demonstrated an adjusted risk increase of 21 percent for suffering a heart attack. RVO is one of the most common causes of visual ...


National Institutes of Health (press release)

Avastin as effective as Eylea for treating central retinal vein occlusion
National Institutes of Health (press release)
Monthly eye injections of Avastin (bevacizumab) are as effective as the more expensive drug Eylea (aflibercept) for the treatment of central retinal vein occlusion (CRVO), according to a clinical trial funded by the National Eye Institute (NEI), part ...

and more »

The New Indian Express

Government initiative for patients with diabetic retinal disorders
The New Indian Express
Other than diabetes, the injection is also helpful for venous occlusion in the retina and age related macular degeneration, an eye disease that affects people at old age. The injection was available at few private hospitals in the State and patients ...

and more »

Head-To-Head Survey: Ohr Pharmaceuticals (OHRP) & Its Competitors
The Ledger Gazette
The company is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion. Its preclinical pipeline of sustained release ...

and more »

New Research on Global Widefield Imaging Systems Market by focusing on Top Companies like Clarity Medical ...
Medgadget (blog)
By technology the market for widefield imaging systems is segmented into diabetic retinopathy, retinopathy of prematurity, pediatric retinal diseases, retinal vein occlusion, ocular oncology, uveitis, chorioretinal diseases, glaucoma, others. By ...

and more »

“Global Widefield Imaging Systems Market” by focusing on Top Companies like Clarity Medical Systems, Visunex ...
Medgadget (blog)
By technology the market for widefield imaging systems is segmented into diabetic retinopathy, retinopathy of prematurity, pediatric retinal diseases, retinal vein occlusion, ocular oncology, uveitis, chorioretinal diseases, glaucoma, others. By ...

and more »

The Pharmaceutical Journal

Bevacizumab as effective as aflibercept for central retinal vein occlusion
The Pharmaceutical Journal
Bevacizumab as effective as aflibercept for central retinal vein occlusion. Clinical Pharmacist1 JUN 2017. Off-label drug is as effective as standard treatment for macular oedema, according to randomised controlled trial. Retinal image showing macular ...


Bevacizumab On Par With Aflibercept in Retinal Vein Occlusion
MedPage Today
Bevacizumab (Avastin) had similar visual acuity outcomes to aflibercept (Eylea) in patients who had macular edema from central retinal vein or hemiretinal vein occlusion, researchers found. In the SCORE2 trial, mean visual acuity letter score (VALS) ...


Comparing Ohr Pharmaceuticals (OHRP) & Its Peers
StockNewsTimes
The company is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion. Its preclinical pipeline of sustained release ...

and more »

Head to Head Contrast: Ohr Pharmaceuticals (OHRP) & Its Competitors
StockNewsTimes
The company is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion. Its preclinical pipeline of sustained release ...

and more »

Comparing Ohr Pharmaceuticals (NASDAQ:OHRP) & Its Competitors
The Ledger Gazette
The company is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion. Its preclinical pipeline of sustained release ...

and more »

Senesco Technologies (SVON) and Ohr Pharmaceuticals (OHRP) Head to Head Contrast
The Ledger Gazette
The company is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion. Its preclinical pipeline of sustained release ...

and more »

News-Medical.net

Central Retinal Vein Occlusion (CRVO)
News-Medical.net
Central retinal vein occlusion (CRVO) is the most common disease of the retinal vessels. It refers to a blockage of the vein draining the retinal tissue at the back of the eye. Occurring mostly in the elderly or middle-aged, it causes a subacute loss ...
US, UK trials underway to compare treatments for CRVOHealio

all 3 news articles »

Ohr Pharmaceuticals (OHRP) & Its Competitors Head to Head Analysis
The Ledger Gazette
The company is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion. Its preclinical pipeline of sustained release ...

and more »

Clearside Biomedical, Inc. (NASDAQ:CLSD) Sees Light Trading Volume with 231 Shares Changing Hands
HugoPress
Its products include CLS-1001 for the treatment of macular edema associated with non-infectious uveitis; CLS-1003 for the treatment of macular edema associated with retinal vein occlusion; and CLS-1002 program for the treatment of wet age-related ...


Clearside Biomedical, Inc. (NASDAQ:CLSD) Short Interest Down by -5.48% – Shares Trading Down
HugoPress
Its products include CLS-1001 for the treatment of macular edema associated with non-infectious uveitis; CLS-1003 for the treatment of macular edema associated with retinal vein occlusion; and CLS-1002 program for the treatment of wet age-related ...

and more »

Science Daily

Surgical eye robot performs precision-injection in patient with retinal vein occlusion
Science Daily
In case of retinal vein occlusion (RVO) there is a blood clot in one of the retinal veins. This leads to reduced eyesight or even blindness in the eye affected. At the moment, treatment consists of monthly injections in the eye that only reduce the ...
Surgeons Perform a Procedure with This Surgical Robot, Making Highly Precise Eye Injection PossibleWccftech

all 3 news articles »

Clearside Biomedical's TANZANITE Extension Study in Patients with Macular Edema Associated with Retinal Vein ...
GlobeNewswire (press release)
... Clearside's proprietary suspension formulation of the corticosteroid triamcinolone acetonide, used together with intravitreally administered EYLEA® (aflibercept) (“intravitreal Eylea”) for the treatment of macular edema associated with retinal vein ...

and more »

Treatment arms for CRVO yield no difference in visual acuity results
Healio
BOSTON — Dexamethasone implant, ranibizumab injections or a combination of the two each yielded no statistically significant difference in visual acuity or central retinal thickness changes in treatment of central retinal vein occlusion, according to ...


Clearside Biomedical, Inc. (NASDAQ:CLSD) Sees Volatile Trading – Up $0.15
First News 24
Its products include CLS-1001 for the treatment of macular edema associated with non-infectious uveitis; CLS-1003 for the treatment of macular edema associated with retinal vein occlusion; and CLS-1002 program for the treatment of wet age-related ...

and more »
» Load more